Page 11 - Pharma Companies

Pharma marketing practices: High-level committee to meet industry on Friday

The UCPMP is voluntary and there is no legal penalty for violating the code

Glenmark Pharma gets US health regulator nod for generic medication

Glenmark Pharmaceuticals on Wednesday said it has received approval from the US health regulator to market Sodium Phenylbutyrate tablets, used in treating urea cycle disorders, in America. The company has received final approval from the US Food and Drug Administration (USFDA) for the product which is a generic version of Horizon Therapeutics' Buphenyl, the Mumbai-based drug maker said in a statement. According to IQVIA sales data for 12-month period ended September 2022, Buphenyl had annual sales of around USD 8.7 million. Glenmark's current portfolio consists of 177 products authorised for distribution in the US marketplace and 46 abbreviated new drug applications (ANDAs) pending approval with the USFDA.

Sun Pharma Q2 PAT rises 10.5% YoY to Rs 2,262 crore on robust sales

Gross sales came in at Rs 10,809.2 crore, growing by 13.1% over Q2 last year

Strong US pipeline, sustained growth trajectory main trigger for Dr Reddy's

Excluding the strong US show led by Revlimid, Q2 was a mixed bag

Uncertainty on revenue growth, margin outlook hits Gland Pharma stock

The injectable manufacturing company expects the margin pressure to persist due to cost pressures and negative operating leverage.

Q2FY23 preview: Modest revenue growth, Ebitda decline seen in pharma cos

While domestic market demand is strong, analysts expect higher raw material and freight costs to affect business in US, other countries; healthy YoY growth seen in hospitals and diagnostics

Lupin inks pact to acquire two inhalation brands from Sunovion for $75 mn

Drug maker Lupin on Thursday said it will acquire two inhalation brands from Sunovion Pharmaceuticals Inc for USD 75 million (around Rs 622 crore). The drug firm has inked a pact with US-based Sunovion to acquire Brovana (arformoterol tartrate) inhalation solution and Xopenex HFA (levalbuterol tartrate) inhalation aerosol. The Mumbai-based firm expects the transaction to be accretive to earnings in the first year. The acquisition of these two brands will expand the company's inhalation product portfolio in the US and strengthen its presence in the respiratory therapy area while continuing to provide patients access to these important medicines, Lupin said in a statement. Brovana is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. Xopenex HFA is a short-acting beta2-adrenergic agonist (SABA), indicated for the treatment or prevention of bronchospasm in adults, ...

Marksans Pharma to acquire Tevapharm's bulk formulations business

Drug firm Marksans Pharma on Tuesday said it has inked a pact with Tevapharm India to acquire its Goa-based bulk pharmaceutical formulations business. The company has entered into a business transfer agreement with Tevapharm to acquire its business relating to the manufacture and supply of bulk pharmaceutical formulations as a going concern on a slump sale basis. The drug firm has agreed to retain the site employees with existing terms of employment, Marksans Pharma said in a regulatory filing. The transaction is in cash consideration and expected to be finalised by April 1, 2023, subject to the closing conditions, it said, but did not specify the deal value. Teva's affiliate Watson Pharma will continue to own and operate Tevapharm's other manufacturing site at Verna, Goa, the drug firm added. Marksans will continue to supply Teva's affiliates with certain products until the end of FY23 as part of the agreement, which can be extended further with mutual agreement, it said. "The .

New Jersey-based Amneal Pharma starts mfg operations for Indian market

The firm already has manufacturing units in four Indian cities, all of which are focused on the export market

Top Headlines: Run-up to Budget 2023-24, India Inc's Q2 earnings, and more

The July-September quarter (second quarter, or Q2) of 2022-23 (FY23) could mark the end of the period of an unprecedented rise in India Inc's earnings in the aftermath of the pandemic

Maiden Pharmaceuticals breaks silence on cough syrup deaths in Gambia

The pharma company Maiden Pharmaceuticals has come under scanner after 66 children died in the Gambia after consuming cough syrup produced in India

Udaan to provide medicine delivery to pharmacies every 4-hour

As part of the new service offering, Udaan will provide medicine delivery to pharmacies every 4-hour with 4 delivery slot options in a day to order medicines across six cities

Centre looking to phase out codeine-based cough syrups, select FDCs

The industry is divided on the issue of phasing out codeine-based cough syrups, which are used by many as intoxicants

DTAB to review 19 fixed-dose combinations drugs, codeine formulations today

CDSCO aims to phase out these combinations and codeine-based drugs in a phased manner

PLI schemes should focus on firms making pharma products: Bharat Biotech

Production-linked incentive schemes should also focus on companies providing packaging materials and other services in addition to manufacturers of branded pharmaceutical items to reduce import dependence, according to Bharat Biotech Executive Director Sai Prasad. He also emphasised on shifting the focus towards innovative pharmaceuticals products in order to enhance the margins for industry players. "We already have policies like production-linked incentive (PLI) schemes and research-based schemes and these policies are going to be very helpful for the sector... It is our view that such policies should also focus on companies which provide goods and services to the pharma industry," Prasad told PTI in an interaction. The incentives also need to be given to single-use consumer companies, raw material packaging firms and other service providers in the pharmaceutical supply chain, he added. "If the ecosystem is strong only then the branded companies could be strong," Prasad said. He

Mankind Pharma files for IPO, could be second largest among pharma firms

The offer for sale is expected to be anywhere between Rs 5000-5500 crore, say sources

SEBI asks pharma companies to disclose details that can impact stock prices

The details that need to be disclosed are new drugs, pending patents, source of raw materials, and new partnerships, among others

Essential medicines list updated, adds 34 new drugs and drops 26

Medicines to treat diabetes, HIV, TB, contraceptives, hormonal medicines included in National List of Essential Medicines

NLEM 2022: Analysts see no major impact pharma companies' growth

The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM include anti-infectives, anti-diabetics, anesthetics, etc

Pharma body clears Micro Labs of charges of spending Rs 1000 cr on freebies

Indian Pharmaceutical Alliance ethics committee submits report to NPPA